Sonesitatug vedotin shows significant survival benefit in advanced gastric cancers
Sonesitatug vedotin demonstrated a statistically significant improvement in overall survival for patients with CLDN18.2-positive advanced gastric/GEJ cancers.
Asset / Drug
Drug and asset intelligence for Sonesitatug with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.